Study is not recruiting and using secondary data sources only
Study is not recruiting and using secondary data sources only
Study Type
OBSERVATIONAL
Subcutaneous Injection
Subcutaneous or Intravenous Injection
Oral, Opthalmic, Subcutaneous or Intravenous Injection
Incidence Rate of Participants With Major Adverse Cardiovascular Events (MACE)
MACE is defined as any fatal or nonfatal myocardial infarction (MI) or stroke (including cerebral infarction, nontraumatic intracerebral hemorrhage, and nontraumatic subarachnoid hemorrhage).
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Serious Infections
Serious infections is defined as inpatient encounter for infections or receiving treatment with intravenous antibiotics, anti-viral or anti-fungal medications.
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Tuberculosis
Tuberculosis is defined as inpatient encounter for active tuberculosis, or outpatient encounter with a dispensing of at least two classes of first-line anti-tuberculosis medications (e.g., isoniazid, rifampin, pyrazinamide, or ethambutol) for a sufficient duration to differentiate prophylaxis and treatment use.
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Opportunistic Infections Excluding Tuberculosis and Herpes Zoster
Opportunistic infections are defined as outpatient or inpatient encounter for opportunistic infections excluding tuberculosis and herpes zoster.
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Serious Hypersensitivity Reactions
Serious hypersensitivity reactions are defined as emergency department (ED) or inpatient encounter for serious hypersensitivity reactions including anaphylaxis.
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Autoimmune Disease
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Autoimmune disease is defined as outpatient or inpatient encounter for systemic lupus erythematosus (SLE).
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Neurologic or Demyelinating Disease
Neurologic or demyelinating disease is defined as outpatient or inpatient encounter for multiple sclerosis (MS), optic neuritis, and the peripheral demyelinating disease Guillain-Barré syndrome.
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Gastrointestinal Adverse Events
Gastrointestinal adverse events are defined as inpatient encounter for gastrointestinal perforation. Gastrointestinal (GI) perforation is defined as perforation of the esophagus, stomach, small intestine, large intestine, and unspecified lower GI.
Time frame: Up to approximately 10 years
Incidence Rate of Participants With Nonmalignant-Hematologic Adverse Events
Nonmalignant-hematologic adverse events are defined as outpatient or inpatient encounter for a non-malignant hematological adverse events (pancytopenia, agranulocytosis and aplastic anemia).
Time frame: Up to approximately 10 years